Cumberland Pharmaceuticals Inc (CPIX) stock
Close on Nov 11, 2026Market cap $91.70MP/E –Yield –
Cumberland Pharmaceuticals Inc saw revenue fall 1.1% to $31.27M over the twelve months to Jun 30, 2026. Free cash flow was $683.90K, down 90.3% from a year earlier. At the latest close the market valued the company at $91.70M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $91.70M
- P/E ratio
- –
- Price to sales
- 2.93
- Price to book
- 5.26
- Dividend yield
- –
- Free cash flow yield
- 0.75%
Fundamentals
- Revenue
- $31.27M
- Net income
- -$10.92M
- EPS, diluted
- -$0.73
- Free cash flow
- $683.90K
- Book value per share
- $1.16
- Diluted shares
- 15M
Trading
- Next earnings
- Mar 2, 2027 (estimated, during market hours)
- Previous close
- $5.30
- Open
- $5.20
- Day's range
- $5.17 – $6.75
- Volume
- 745,374
- Average volume (20 days)
- 211,487
- Beta (5 years)
- 0.29
- 52-week range
- $1.85 – $9.28
- RSI (14 days)
- 51.6
- Volatility (1 year)
- 103.6%
- Relative volume
- 7.17×
- WACC
- 7.4%
On 1 of our idea list: Yields that look too good (a warning list)
Market cap history
Month-end market cap since 2010, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | CPIX | S&P 500 | Difference | CPIX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -12.9% | -2.4% | −10.5 pts | ||
| 3 months | -23.1% | -1.2% | −22.0 pts | ||
| Year to date | +98.3% | +12.3% | +86.0 pts | ||
| 1 year | +294.6% | +12.4% | +282.2 pts | ||
| 3 years | +345.9% | +78.8% | +267.1 pts | +64.6% | +21.4% |
| 5 years | +193.4% | +75.2% | +118.2 pts | +24.0% | +11.9% |
| 10 years | +58.5% | +311.1% | −252.6 pts | +4.7% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Cumberland Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- News
- News
- News
- Results
About Cumberland Pharmaceuticals
Pharmaceutical Preparations
Cumberland Pharmaceuticals Inc. is a specialty biopharmaceutical company that acquires, develops, and commercializes branded prescription pharmaceuticals. Its core business focuses on hospital acute care, gastroenterology, and oncology. The company's commercial portfolio includes Acetadote for acetaminophen toxicity, Caldolor for pain and fever, Kristalose for constipation, Sancuso for chemotherapy-induced nausea and vomiting, Vaprisol for hyponatremia, Vibativ for serious bacterial infections, and Talicia for Helicobacter pylori infections. Cumberland distributes its medicines primarily to wholesale pharmaceutical distributors in the United States, promoting its therapies to physicians, hospitals, clinics, and medical specialists through hospital, field, and oncology sales forces.
Company profile, executives and historyCumberland Pharmaceuticals stock: common questions
What is Cumberland Pharmaceuticals's stock price?
CPIX closed at $6.12 on Nov 11, 2026, up 15.47% on the day. Over the past 52 weeks it traded between $1.85 and $9.28.
What is Cumberland Pharmaceuticals's market cap?
Cumberland Pharmaceuticals was worth $91.70M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is CPIX's P/E ratio?
Cumberland Pharmaceuticals lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.73), so it has no meaningful P/E ratio.
How much revenue does Cumberland Pharmaceuticals make?
Cumberland Pharmaceuticals reported revenue of $31.27M for the twelve months to Jun 30, 2026, down 1.1% from a year earlier.
Does Cumberland Pharmaceuticals pay a dividend?
No. Cumberland Pharmaceuticals has not paid a cash dividend over the last twelve months.
When does Cumberland Pharmaceuticals report earnings next?
Cumberland Pharmaceuticals is expected to report Q4 FY2026 results on Mar 2, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has CPIX stock performed over the past year?
Including dividends, CPIX returned +294.6% over the past year, against +12.4% for the S&P 500.
How many CPIX shares are sold short?
0M shares were sold short at the latest FINRA report, 10.14% of the float, or 1.8 days of average trading volume.
Who are Cumberland Pharmaceuticals's competitors?
Companies most similar to Cumberland Pharmaceuticals by business, industry and size include TNXP, LXRX, MCUJF, VRCA, CASIF.
See a number that looks wrong?